medicare glp-1 coverage obesity CMS Extends Medicare's Short-Term Bridge Program for Drug Medicare weight loss drugs: Who

Ozempic Mounjaro Mounjaro is fairly new, having been released in 2022

These B-series compounds (JWU B007 through B014) were obtained by modifying the annulation reaction so that the Lewis acid catalyst GaBr 3 was replaced with 20 mol% of TfOH (see Supplemental Material)

Inulin modulates the gut microbiome (more SCFAs more GLP-1)

Patents will reshape the landscape: semaglutide loses composition-of-matter exclusivity in 2031, while tirzepatide extends to 2036, creating different windows for biosimilar entry

GLP-1 (glucagon-like peptide-1) medications were originally developed to treat Type 2 diabetes, but researchers discovered something remarkable: people were also losing significant amounts of weight

GLP-1R-targeted nanomedicines often carry multifunctional payloads, such as GLP-1 analogs, chemotherapeutic agents, and diagnostic compounds, which do not conform to conventional monotherapy trial frameworks [558, 559]